Atlas Trials

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

Clinical trial NCT06610682 · RECRUITING

Trial details

NCT number
NCT06610682
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
BRAF V600E Mutation
Start date
2025-04-07
Primary completion
2027-06-30
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.